Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Tony Mok(Chinese University of Hong Kong), R. Linke, Rickard Sandin(Pfizer (Sweden)), Seiji Niho(Dokkyo Medical University), Fumito Tsuji, Rafael Rosell(Hospital Universitario Dexeus), Ying Cheng(Jilin Province Tumor Hospital), Eric Sbar(Pfizer (United States)), Sashi Nadanaciva(Pfizer (United States)), Xiangdong Zhou(Army Medical University), Tao Wang(Pfizer (United States)), Kazuhiko Nakagawa(Osaka Red Cross Hospital), J. Corral(Hospital Universitario Virgen del Rocío), Jane Liang White(Pfizer (United States)), Adam Płużański(The Maria Sklodowska-Curie National Research Institute of Oncology), Maria Rita Migliorino(Carlo Forlanini Hospital), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 1,206
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k